The First Cohort — Nocturnal Dark Broadsheet homepage featuring eleven evidence-anchored medical research stories across Cancer, Metabolic, Drugs, Infectious Disease, Brain, Autoimmune, Nutrition, and Investigations beats.

The First Cohort

Medical research, with the receipts

Cancer

A Korean lab found cancer’s DNA-repair off-switch. In a mouse.

A tool compound strips the DNA-repair proteins tumors use to dodge PARP inhibitors. Preclinical only — but the gap between treated and control animals is the story.

Tumor clearance at 8 weeks Tumor clearance at 8 weeks % Treated 94% Control 12% 0 25 50 75 100 Source: Korean lab preclinical study, n=controlled trial; mouse model only


Metabolic

Where your sodium actually comes from

~71% of dietary sodium arrives via processed food. The saltshaker accounts for 6–20%. The numbers make most restaurant-labeling policy look like theater.


Drugs & FDA

Europe had this sunscreen in 1999. The FDA approved it Tuesday.

Twenty-seven years of regulatory lag, distilled into one approval notice. What the hold-up actually was, and what it wasn’t.



Infectious Disease

A DoD-funded fentanyl vaccine is headed to Phase 1

Antibodies don’t stop a supply chain. The trial design is sound. The policy translation is another matter entirely.


Brain & Aging

The Alzheimer’s drug that bets the plaques are a symptom

If amyloid is downstream, clearing it treats a signal, not a cause. The mechanism argument is now the trial’s biggest liability.


Autoimmune

Fish oil rewired the T-cells in non-obese diabetic rats

Cancer

ALTAIR missed its endpoint. The press tour found something else.